一项评估曲妥珠单抗生物类似药（赫赛汀）联合治疗医生选择方案（TPC）在经大量预处理的 HER2+转移性乳腺癌（KCSG BR 18-14/KM10B）患者中的疗效的 II 期研究。
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).
机构信息
Center for Breast Cancer, National Cancer Center, Goyang, South Korea.
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
出版信息
Breast. 2022 Oct;65:172-178. doi: 10.1016/j.breast.2022.08.002. Epub 2022 Aug 17.
Abstract
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
摘要
我们研究了曲妥珠单抗生物类似药 Herzuma®联合医生选择的治疗方案（TPC）治疗至少两种曲妥珠单抗为基础的化疗失败的 HER2+转移性乳腺癌（MBC）患者的疗效和安全性。
Zotero 插件